openPR Logo
Press release

The prefilled syringes market is estimated to be worth over USD 2.5 billion in 2030, predicts Roots Analysis

01-04-2021 06:42 AM CET | Health & Medicine

Press release from: Roots Analysis

The prefilled syringes market is estimated to be worth over USD

Despite having been available for more than two decades, the demand for prefilled syringes continues to grow, given the numerous benefits they offer over conventional injectable drug delivery systems

Roots Analysis is pleased to announce the publication of its recent study, titled, “Prefilled Syringes Market (5th Edition), 2020-2030.”

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html

The report features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed overview of the current market landscape of companies engaged in manufacturing prefilled syringes.
A detailed overview of the current market landscape of companies that are developing drugs in combination with prefilled syringes.
A detailed competitiveness analysis of the various prefilled syringes that we came across..
A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with prefilled syringes in the near future.
An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development).
An analysis of the various prefilled syringe combination product-related initiatives of big pharma players.
A review of the landscape of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of relevant parameters.
An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.
Brief discussions of currently available specialty syringes.
A case study on companies that are engaged in the manufacturing of autoinjectors.
Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Target therapeutic area
Autoimmune disorders
Infectious diseases
Neurological disorders
Blood disorders
Oncological disorders
Psychiatric disorders
Respiratory disorders
Cardiovascular disorders
Metabolic disorders
Ophthalmic diseases
Orthopedic disorders
Others
Type of syringe
Specialty syringes
Type of syringe barrel material
Glass
Plastic
Number of barrel chambers
Single chamber
Dual chamber
Key geographical regions
North America
Europe
Latin America
Asia Pacific
Middle East and Africa World
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies
Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals
Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical
Marco Pederiva, Marketing & Sales Director, Lonstroff
Jesse Fourt, Design Director, IDEO
Anonymous, Chief Executive Officer, Small-sized Medical Device Company

Key companies covered in the report
Becton Dickinson
West Pharmaceutical
Gerresheimer
Ompi
Schott
Nipro
WEGO Prefills Pharmaceutical Packaging
Taisei Kako
Terumo
Aguettant
Arte
JO Pharma
Pfizer Injectables
Shandong Pharmaceutical Glass
Shandong Zibo Minkang Pharmaceutical Packing
Vetter Pharma

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html

Other Recent Offerings
1. Global Autoinjectors Market (3rd Edition), 2020-2030
2. Novel Vaccine Delivery Devices Market, 2019-2030
3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
4. Medical Device Labels Manufacturing Market, 2019 - 2030

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The prefilled syringes market is estimated to be worth over USD 2.5 billion in 2030, predicts Roots Analysis here

News-ID: 2220038 • Views:

More Releases from Roots Analysis

Autoinjectors Market to Reach USD 299 Billion by 2035 at 5.7% CAGR | SHL Medical, Ypsomed, Owen Mumford
Autoinjectors Market to Reach USD 299 Billion by 2035 at 5.7% CAGR | SHL Medical …
The global autoinjectors market, valued at USD 170 billion in 2025, will reach USD 181 billion in 2026 and climb to USD 299 billion by 2035, advancing at a CAGR of 5.7% over the forecast period. The growth reflects accelerating demand for self-administration devices across chronic disease management, a wave of biosimilar launches entering autoinjector formats, and a measurable shift in patient care from clinical settings to home environments. To access
Antiviral Drugs Market to Reach USD 127 Billion by 2035, Growing at 6.1% CAGR | Gilead Sciences, Pfizer, AbbVie
Antiviral Drugs Market to Reach USD 127 Billion by 2035, Growing at 6.1% CAGR | …
The global antiviral drugs market, valued at USD 69 billion in 2025, will reach USD 74 billion in 2026 and climb to USD 127 billion by 2035, advancing at a CAGR of 6.1% over the forecast period. Infectious disease burden, accelerating R&D pipelines, and the post-pandemic push for novel antivirals are collectively reshaping this market into one of the pharmaceutical sector's most active growth categories. To explore the complete findings, request
Antibody Drug Conjugate (ADC) Market to Reach $28.41 Billion by 2035 | AstraZeneca, Daiichi Sankyo, Roche
Antibody Drug Conjugate (ADC) Market to Reach $28.41 Billion by 2035 | AstraZene …
The global antibody drug conjugate (ADC) market, valued at USD 15.29 billion in 2025, will grow to USD 18.69 billion in 2026 and reach USD 28.41 billion by 2035, advancing at a CAGR of 4.8% through the forecast period. With 19 approved therapies already on the market and an active clinical pipeline spanning hundreds of programs, the ADC sector has moved well past proof-of-concept and into a sustained commercial expansion
Antibody Discovery Services and Platforms Market to Reach $6.3 Billion by 2035 at 12.3% CAGR | WuXi Biologics, Genmab, ImmunoPrecise Antibodies
Antibody Discovery Services and Platforms Market to Reach $6.3 Billion by 2035 a …
The global antibody discovery market, valued at $2.0 billion in 2025, will climb to $2.2 billion in 2026 and reach $6.3 billion by 2035, compounding at a CAGR of 12.3% over the forecast period. Surging demand for targeted biologics, a record pace of monoclonal antibody approvals, and the accelerating adoption of AI-assisted discovery platforms are converging to make this one of the most commercially consequential segments in the life sciences

All 5 Releases


More Releases for Pharma

Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring